AIM ImmunoTech Inc. (New York Stock Exchange Arca:AIM)
| Market Cap | $4.57M-91.6% |
| Revenue (ttm) | $91.00K-18.8% |
| Net Income | -$14.13M+10.3% |
| EPS | -$0.35+70.2% |
| Shares Out | 39.92M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,244,557 |
| Open | $0.12 |
| Previous Close | $0.12 |
| Day's Range | $0.11 - $0.13 |
| 52-Week Range | $0.11 - $1.88 |
| Beta | 1.31 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Mar 26, 2027 |
About AIM
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
AIM ImmunoTech Inc. Stock Analysis — InsiderScore
AIM ImmunoTech Inc. scored higher than 47% of companies evaluated by InsiderBuying, and ranked 44th out of 110 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at AIM ImmunoTech Inc. bought $58.8K of stock across 14 purchases in the last 90 days, the largest of them $6.5K.
The average purchase added about 13% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 26, 2027Earnings report
$AIM stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in AIM holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by AIM's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
AIM Estimated quarterly lobbying spending
Source: U.S. Senate LDA
AIM Revenue by Segment or Geography
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New AIM patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to AIM from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from AIM’s recent data — informational, not investment advice
What’s Behind the Score
News check: Major clinical catalysts expected (pancreatic cancer Phase 2 data Q1 2027) combined with routine corporate updates support moderately bullish sentiment.
Recent Insider Activity
Insider Score Trend Over Time
+10.6 since Sep 24Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
